News
Trastuzumab Deruxtecan in Patients with HER2+ Metastatic Breast Cancer
Last year, results of studies published in the Lancet journal demonstrated a significant clinical benefit of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer (mBC) pre-treated with anti-HER2 therapy, in the 2nd or later lines of treatment compared to trastuzumab emtansine (DESTINY-Breast03 study, second interim overall survival analysis) and after failure of trastuzumab emtansine compared to physician's choice of therapy (DESTINY-Breast02 study).
Benefits of Time-Limited CLL Therapy
The advent of new targeted molecules has significantly influenced the possibilities of therapy for…
Improving treatment outcomes of HF with preserved ejection fraction according to JACC: What does the success of gliflozins mean for the future?
The Journal of the American College of Cardiology (JACC) recently issued a scientific statement in…
Current Reimbursement Conditions for the Dual Inhibitor IL-4/IL-13 Dupilumab
The biologic dupilumab is approved for the treatment of several diseases with type 2 inflammation.…
Digital Bridge Between the Brain and Spine: How an Implant Restored Walking Ability to a Paralyzed Patient − Case Study
When a spinal cord injury occurs, communication between the brain and peripheral nerves is…
A Cloned Monkey Survived to Adulthood for the First Time. Will We Soon Be Able to Clone Humans?
A macaque named ReTro, born as a result of a cloning experiment by Chinese scientists, has reached…
Can we properly manage osteoporotic fractures?
Osteoporotic fractures are associated with increased morbidity and mortality and often lead to an…
Meta-analysis of the Effectiveness of Romosozumab in the Treatment of Postmenopausal Osteoporosis
Osteoporosis is a prevalent disease with unmet therapeutic needs. Whether the anti-sclerostin…
Lurasidone in a Patient with Paranoid Schizophrenia and Asperger's Syndrome – A Case Study
Lurasidone is an effective and very gentle antipsychotic which is establishing a prominent position…
Clinical Significance of Smaller Gaps Between Strengths of Levothyroxine Preparations in the Treatment of Hypothyroidism
Many levothyroxine preparations have relatively large intervals between doses (25 µg, 50 µg, and 75…